About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The VHIR Infectious Diseases research group is made up of medical professionals, with healthcare and clinical or basic translational research activities; of Biomedicine dedicated to basic research; and Nursing, with activities to support clinical research.
The group's lines of research are mainly focused on four areas:
Infections related to immunosuppression. Includes infectious diseases related to immunocompromised patients, solid organ or hematopoietic stem cell transplant recipients and recipients of biological therapies.
Sexually transmitted diseases, including HIV infection and other highly prevalent infections in our country (syphilis, gonorrhea, lymphogranuloma venere or infections caused by the human papillomavirus).
Infections related to health care, with special emphasis on those difficult to treat (cardiovascular infections or infections related to prosthetic materials) or caused by multi-resistant pathogens (MDRO) or affecting vulnerable populations.
Global Health and Tropical Diseases with special emphasis on prevalent diseases in our environment that affect the immigrant or displaced population.
PMID: 31701864 Journal: AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE Year: 2020 Reference: Am J Trop Med Hyg. 2020 Jan;102(1):159-163. doi: 10.4269/ajtmh.19-0550. Impact factor: 2.126 Publication type: Paper in international publication Authors: Molina, Israel, Silgado, Aroa, Moure, Zaira, Bosch-Nicolau, Pau, Salvador, Fernando, Sanchez-Montalva, Adrian, Martinez-Gallo, Monica, Sulleiro, Elena, Franco-Jarava, Clara, Sao Aviles, Augusto et al. DOI: 10.4269/ajtmh.19-0550
PMID: 31674901 Journal: EMERGING INFECTIOUS DISEASES Year: 2020 Reference: Emerg Infect Dis. 2020 Jan;26(1):150-153. doi: 10.3201/eid2601.181685. Epub 2020 Jan 17. Impact factor: 6.259 Publication type: Paper in international publication Authors: Salvador, Fernando, Sanchez-Montalva, Adrian, Espasa, Mateu, Molina, Daniel, de Ory, Fernando, Sanchez-Seco, M Paz, Molina, Israel, Diaz-Lagares, Candido, Martinez, Miguel J, Pumarola, Tomas et al. DOI: 10.3201/eid2601.181685
PMID: 31539031 Journal: European Heart Journal-Cardiovascular Imaging Year: 2020 Reference: Eur Heart J Cardiovasc Imaging. 2020 Jan 1;21(1):24-33. doi: 10.1093/ehjci/jez222. Impact factor: 4.841 Publication type: Paper in international publication Authors: Fernandez-Hidalgo, Nuria, Permanyer, Eduard, Cuellar-Calabria, Hug, Romero-Farina, Guillermo, Rios, Remedios, Almirante, Benito, Castell-Conesa, Joan, Escobar, Manuel, Ferreira-Gonzalez, Ignacio, Tornos, Pilar et al. DOI: 10.1093/ehjci/jez222
PMID: 31530462 Journal: JOURNAL OF ARTHROPLASTY Year: 2020 Reference: J Arthroplasty. 2020 Jan;35(1):247-254. doi: 10.1016/j.arth.2019.07.043. Epub 2019 Aug 19. Impact factor: 3.709 Publication type: Paper in international publication Authors: Corro, Sebastian, Vicente, Matias, Rodriguez-Pardo, Dolors, Pigrau, Carles, Lung, Mayli, Corona, Pablo S et al. DOI: 10.1016/j.arth.2019.07.043
PMID: 30722752 Journal: INTERNATIONAL JOURNAL OF STD & AIDS Year: 2019 Reference: Int J STD AIDS. 2019 May;30(6):623-625. doi: 10.1177/0956462419825896. Epub 2019 Feb 5. Impact factor: 1.501 Publication type: Paper in international publication Authors: Isabel Lazaro-Simo, Anna, Esperalba-Esquerra, Juliana, Vall-Mayans, Marti et al. DOI: 10.1177/0956462419825896
PMID: 30723941 Journal: PHARMACOTHERAPY Year: 2019 Reference: Pharmacotherapy. 2019 Apr;39(4):501-507. doi: 10.1002/phar.2227. Epub 2019 Mar 22. Impact factor: 3.045 Publication type: Paper in international publication Authors: Navarro, Jordi, Santos, Jose Ramon, Silva, Ana, Burgos, Joaquin, Falco, Vicenc, Ribera, Esteban, Imaz, Arkaitz, Curran, Adrian et al. DOI: 10.1002/phar.2227
PMID: 30315920 Journal: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS Year: 2019 Reference: Int J Antimicrob Agents. 2019 Feb;53(2):165-170. doi: 10.1016/j.ijantimicag.2018.10.003. Epub 2018 Oct 10. Impact factor: 4.615 Publication type: Paper in international publication Authors: Almirante, Benito, Bartolome, Rosa, Gonzalez-Lopez, Juan Jose, Pigrau, Carlos, Rodriguez-Pardo, Dolors, Escola-Verge, Laura, Fernandez-Hidalgo, Nuria et al. DOI: 10.1016/j.ijantimicag.2018.10.003
PMID: 30587519 Journal: NEUROLOGY Year: 2019 Reference: Neurology. 2019 Feb 5;92(6):296-298. doi: 10.1212/WNL.0000000000006801. Epub 2018 Dec 26. Impact factor: 8.689 Publication type: Paper in international publication Authors: Pappolla, Agustin, Midaglia, Luciana, Boix Rodriguez, Claudia P, Puig, Adaia Albasanz, Lung, Maiylyi, Camps, Isabel Ruiz, Castillo, Joaquin, Mulero, Patricia, Arrambide, Georgina, Rodriguez-Acevedo, Breogan et al. DOI: 10.1212/WNL.0000000000006801
The new protocol has the same efficacy as the standard one, but only a quarter of the duration, reducing dropout rates and side effects.
The initiative, carried out at the Consulate of Bolivia, has resulted in 307 new tests for the diagnosis of Chagas disease
The study shows that blocking the KLRG1 receptor helps to recover the activity of the natural killer cells of the immune system and reactivate the virus reservoir to fight infection.
